CTGTAC Discussion Topic #1

Discuss whether the single-arm Study IGNYTE, as designed and conducted, allows for a reliable determination on the expected response rate and durability of response in the proposed population.

CTGTAC Discussion Topic #2

Discuss the clinical meaningfulness of the response rate and duration of response reported in Study IGNYTE and if the observed responses are indicative of systemic anti-tumor activity attributable to vusolimogene oderparepvec.

CTGTAC Voting Question

Are the efficacy results from IGNYTE evaluable and clinically meaningful?

Please vote “Yes” or “No” or “Abstain”